Cargando…
Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
Imatinib mesylate (IM) has dramatically improved the outcomes of gastrointestinal stromal tumor (GIST) patients. However, the clinical responses of IM may considerably vary among single individuals. This study aimed to investigate the influences of genetic polymorphisms of drug-metabolizing enzyme (...
Autores principales: | Liu, Jing, Chen, Zhiyu, Chen, Hanmei, Hou, Yingyong, Lu, Weiqi, He, Junyi, Tong, Hanxing, Zhou, Yuhong, Cai, Weimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372619/ https://www.ncbi.nlm.nih.gov/pubmed/28335376 http://dx.doi.org/10.3390/ijms18030603 |
Ejemplares similares
-
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017) -
Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007) -
Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015) -
Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018) -
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)